Loading clinical trials...
Loading clinical trials...
A Multi-center, Randomized, Open-label, Mechanism of Action Trial on the Biological Effects of the Therapeutic Cancer Vaccine Stimuvax® (L-BLP25) in Rectal Cancer Subjects Undergoing Neoadjuvant Chemoradiotherapy
Conditions
Interventions
Tecemotide (L-BLP25)
cyclophosphamide (CPA)
+1 more
Locations
1
Netherlands
NKI (Nederlands Kanker Instituut)
Amsterdam, Netherlands
Start Date
February 1, 2012
Primary Completion Date
June 1, 2014
Completion Date
June 1, 2014
Last Updated
January 13, 2017
NCT04704661
NCT06696768
NCT04929028
NCT05489211
NCT04674267
NCT06625775
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions